Premium
Inhibition of cell proliferation in human breast tumor cells by antisense oligonucleotides against facilitative glucose transporter 5
Author(s) -
Chan K.K.,
Chan Judy Y.W.,
Chung Karen K.W.,
Fung KwokPui
Publication year - 2004
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.20270
Subject(s) - estrogen receptor , tamoxifen , breast cancer , cancer research , biology , glucose transporter , cell growth , estrogen , mcf 7 , cell , endocrinology , medicine , cancer , biochemistry , human breast , insulin , genetics
In recent years, successful examples of antisense oligonucleotide (AS) therapy for genetic diseases have stimulated scientists to investigate its application on cancer diseases. AS can be used to down‐regulate the mRNA and protein expression by annealing to specific region of the target mRNA which is responsible for the malignancy. Glucose transporter 5 (Glut5) is a tissue specific transporter that can be found on breast cancer tissues but not on normal breast tissues. Therefore, it is of clinical interest to investigate whether AS against Glut5 mRNA can tackle breast cancer. In this study, two cell lines, MCF‐7 which is estrogen‐receptor positive and MDA‐MB‐231 which is estrogen‐receptor negative, were used to mimic breast cancer tissues at early and late stages, respectively. A 15‐base sequence around the start codon of Glut5 was used. It was found that AS against Glut5 exerted anti‐proliferative effect on both of these two breast tumor cell lines and seemed to exert its effect via the suppression of expression of Glut5 proteins in the cells. AS against Glut5 exhibited no effect on human hepatoma HepG2 cells which do not possess any Glut5. The results imply an alternative way in treating breast tumor as the AS against Glut5, unlike tamoxifen, takes effect on breast tumor cells via suppressing the expression of Glut5 that they specifically possess, and regardless whether the breast tumors are estrogen dependent or not. © 2004 Wiley‐Liss, Inc.